<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18257">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01830010</url>
  </required_header>
  <id_info>
    <org_study_id>CKRP203A2105</org_study_id>
    <nct_id>NCT01830010</nct_id>
  </id_info>
  <brief_title>A Single Arm, Open-label Study to Evaluate the Safety and Tolerability of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies</brief_title>
  <official_title>A Single-arm, Open-label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KRP203 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-arm, open-label study to evaluate the safety, tolerability and pharmacokinetics of
      KRP203 in patients undergoing allogeneic hemopoietic stem cell transplant for hematological
      malignancies
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Number of participants with Adverse Events as a Measure of safety</measure>
    <time_frame>111 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability of KRP203 in patients undergoing allogeneic hematopoetic stem cell transplant for hematological malignancies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of KRP203: Area under the Plasma Concentration-time Curve (AUC)</measure>
    <time_frame>111 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The main PK parameters will be determined in whole blood using non-compartmental methods. Pk parameters being measured are: AUCtau AUC during a dosing interval (tau) of 24 hours [h.ng/mL] , AUCtauR Molar ratios between KRP203-P and KRP203 based on Cmax or AUCtau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of KRP203: Observed Maximum Plasma Concentration Following Drug Administration (Cmax)</measure>
    <time_frame>111 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax Maximum (peak) blood drug concentration after drug administration [ng/mL]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of KRP203: Time to reach the maximum concentration after drug administration</measure>
    <time_frame>111 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax Time to reach maximum (peak) concentration [ng/mL]</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>KRP203</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients to receive 3mg of KRP203 for 111days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRP203</intervention_name>
    <description>All subjects will receive KRP203 for 111 days</description>
    <arm_group_label>KRP203</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients aged 18 to 65 years, inclusive

          -  Patients must have a hematological malignancy that as per standard medical practice
             requires myeloablative conditioning (including short term myeloablative reduced
             intensity conditioning) followed by allogeneic hematopoetic stem cell transplant

               -  Karnofsky Performance status â‰¥60%.

               -  Suitable stem cell source available according to the graft selection algorithm
                  using T-cell replete peripheral stem cells as a graft source

        Exclusion Criteria:

          -  Resting heart rate below 55

          -  Significant cardiac disease (such as arrhytmia, heart failure) or any significant
             condition which in the investigators opinion would make the patient ineligible

               -  Previous allogeneic HSCT

               -  Any drug required that is not compatible with KRP203 (e.g. beta-blockers or
                  anti-thymocyte globulin)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 9, 2013</lastchanged_date>
  <firstreceived_date>April 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
